Last reviewed · How we verify
Jublia®
Jublia is a topical antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in the fungal cell membrane.
Jublia is a topical antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Onychomycosis (fungal nail infection) caused by dermatophytes, non-dermatophyte molds, and yeasts.
At a glance
| Generic name | Jublia® |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Azole antifungal |
| Target | Squalene epoxidase (fungal) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Efinaconazole, the active ingredient in Jublia, is an azole antifungal that blocks the conversion of squalene to lanosterol by inhibiting the enzyme squalene epoxidase. This disruption of ergosterol biosynthesis compromises the integrity and function of the fungal cell membrane, leading to fungal cell death. It is applied topically as a solution for localized fungal infections.
Approved indications
- Onychomycosis (fungal nail infection) caused by dermatophytes, non-dermatophyte molds, and yeasts
Common side effects
- Application site erythema
- Application site pruritus
- Nail discoloration
- Skin irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jublia® CI brief — competitive landscape report
- Jublia® updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI